Tofflon Science and Technology Group (300171) Fair Value & Analysis
Healthcare · CN · Market cap 8.7B CNY
Fair value as of: Jul 7, 2026
From 26 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from ¥8.78 to ¥7.36 (−16.2%) since Jun 24, 2026. Share price +12.1% over the past month.
A solid business, but screening 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥7.36). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range ¥9.50 – ¥58.85 · fair‑value band ¥4.70 – ¥7.36 · the ¥12.86 price screens above the ¥7.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Tofflon Science and Technology Group (300171) currently trades at ¥12.86, while our model-based Fair Value estimate is ¥7.36, implying the stock looks roughly 42.8% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Tofflon Science and Technology Group generated revenue of 5.2B CNY at a net margin of 4.0%. Revenue declined 2.5% year over year. It earns a return on equity of 2.7%. The balance sheet holds a net cash position of 2.5B CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥4.70 (bear case) to ¥7.36 (bull case); at ¥12.86, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 36% below its 52-week high and 20% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -43%, 300171 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥14.64) versus Dividend Discount (¥1.62). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 55 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering.
Full company description
Tofflon Science and Technology Group Co., Ltd. engages in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laboratory; instruments, including cell therapy and nucleic acid drugs instruments, and table reactor; cryopreservation system for seeds and biological samples, and freeze-thaw system of biological stock solution; and single use technology, such as bioreactor, liquid distribution system, sterile bag, process chromatography, membrane filtration system, and others. It also provides culture medium, such as cell and gene therapy, biomacromolecule drugs, tobitec feeding medium, and other series; bioreactor and fermentation systems, cell factory, perfusion, and complementary systems; preparation systems, such as bio-process vessel and piping, common solutions, and complex injectable formulation systems; and separation and purification systems, including disc centrifuge membrane filtration, chromatography system and columns, alkali lysis, slurry tank, and filters. In addition, the company offers freeze-drying system, including laboratory, production, and special application freeze-drying products, as well as loading and unloading system; and packaging systems, such as packaging solutions, cartoner machine, top-load cartoner machines, bilster machine, solid bottling equipment, labelling machine, and case packer with palletizer machines. Further, it provides resins, API, isolator system, cleaning and sterilization, filling line, and inspection system products; and engineering services. The company was formerly known as Shanghai Tofflon Science and Technology Co., Ltd. Tofflon Science and Technology Group Co., Ltd. was founded in 1993 and is headquartered in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Tofflon Science and Technology Group reported revenue of ¥5.2B in FY2025 versus ¥4.2B in FY2021, a compound +5.7%/yr. Reported net income was ¥200M in FY2025, compounding −29.9%/yr from FY2021.
300171 screens 43% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Tofflon Science and Technology Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Tofflon Science and Technology Group (300171) overvalued or undervalued?
What is the fair value of 300171?
What is the quality score of 300171?
What is the revenue of Tofflon Science and Technology Group (300171)?
What is the net profit margin of 300171?
Does Tofflon Science and Technology Group pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Tofflon Science and Technology Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.